HAE vs TXG
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
HAE exhibits strong fundamental health with a Piotroski F-Score of 7/9, indicating a robust financial trajectory. While the stock is currently trading above its Graham Number ($39.87), it remains significantly undervalued relative to its growth-based intrinsic value ($107.08) and a PEG ratio of 0.92. Despite a bearish technical trend and slight revenue contraction (-2.70%), the company demonstrates exceptional operational efficiency with 28.4% earnings growth and a consistent track record of beating EPS estimates. The divergence between strong internal fundamentals and poor price performance suggests a value opportunity.
TXG exhibits a stark divergence between its strong balance sheet liquidity and its poor operational health, evidenced by a weak Piotroski F-Score of 2/9. While the company maintains a very low Debt/Equity ratio (0.11) and a robust Current Ratio (4.46), revenue growth has stagnated at 0.60% YoY. The stock is currently trading at a significant premium with a Forward P/E of 114.85, despite negative profit margins. Recent price recovery is strong, but insider selling and bearish technical trends suggest caution.
Compare Another Pair
Related Comparisons
HAE vs TXG: Head-to-Head Comparison
This page compares Haemonetics Corporation (HAE) and 10x Genomics, Inc. (TXG) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.